Lectures and seminars Guest seminar - Hugues de Thé, Collège de France
Title: PML nuclear bodies: biogenesis, biochemical function(s) and physiopathology.
Time and location: 3pm in D1012 Biomedicum floor 10, September 26
Host: Maria Masucci
Hugues de Thé M.D. Ph.D. is Professor of molecular oncology at the Collège de France and physician at Hospital St. Louis, Paris. After making significant contributions to Retinoic Acid signaling during his MD/PhD training, he played a key role in the discovery of the PML/RARA oncoprotein, the driver of acute promyelocytic leukemia. Since, he investigated how PML/RARA drives leukemogenesis and the mechanisms underlying the exquisite clinical response to RA and arsenic. This led him to address issues of transcriptional control, cell biology, proteolysis and mouse modeling. In particular, he established the key role of therapy-induced PML/RARA degradation and PML nuclear bodies in APL response, crafting the physio-pathological bases for definitive curative regimens, first established in mice and subsequently in patients.
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.
de Thé H, Pandolfi PP, Chen Z
Cancer Cell 2017 11;32(5):552-560
Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
Ablain J, Rice K, Soilihi H, de Reynies A, Minucci S, de Thé H
Nat Med 2014 Feb;20(2):167-74
Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
Ablain J, Leiva M, Peres L, Fonsart J, Anthony E, de Thé H
J Exp Med 2013 Apr;210(4):647-53